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INTRODUCTION
Chronic kidney disease (CKD) is a significant public health
problem in the world and has a remarkable impact on car-
diovascular morbidity and mortality in patients with end-
stage renal disease (ESRD) (Foley et al., 1998). In Latvia,
there were estimated 58.7 (Locatelli et al., 2004) and 69.1
(Cannata-Andia et al., 2007) incident patients per million
population with ESRD in 2002 and 2005, respectively. In
addition, the prevalence of patients with renal replacement
therapy (RRT) significantly rose during five years and ac-
counted for 368.6 patients per million population in 2006
(London, 2008). Diabetic kidney disease is the leading
cause of end-stage renal disease (ESRD) in USA and
Europe (Ritz, 1999). In Latvia, 23% of the ESRD patients
have been reported to suffer from diabetes mellitus (Ku-
zema et al., 2008). An important aspect in the management
of CKD is to evaluate risk factors and underlying causes of
development of chronic kidney damage (McClellan et al.,
2003), which may be diabetes, hypertension, proteinuria,
metabolic disorders and anaemia (Levin, 2001). The role of
anaemia in CKD has received much attention of nephrolo-
gists. In addition, with the beginning of the erythropoietin
era, the treatment of renal anaemia is considered as a sig-
nificant in the possible delaying of progression of CKD
(Rossert et al., 2002).
The aims of the study were: to assess the causes of CKD; to
analyse the prevalence of anaemia based on the current
guidelines for anaemia management in CKD (Kidney Dis-
PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 64 (2010), No. 3/4 (668/669), pp. 137–143.
DOI: 10.2478/v10046-010-0027-4
RENAL ANAEMIA: THE ROLE OF HAEMOGLOBIN CONTROL
IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Viktorija Kuzema*,**, Aivars Pçtersons*,**, Harijs Èeròevskis*,**, and Aivars Lejnieks*,***
* Rîga Stradiòð University, Dzirciema iela 16, Rîga, LV-1007, LATVIA; E-mail: viktorija.kuzema@gmail.com
** Pauls Stradiòð Clinical University Hospital, Rîga, Pilsoòu iela 13, LV-1002, LATVIA
* Rîga Eastern Hospital, Hospital ”Linezers”, Rîga, LV-1006, LATVIA
Communicated by Igors Aksiks
Chronic kidney disease (CKD) is a significant and prevalent health problem in the world. Anaemia
is one of the most common manifestations in patients with CKD. The correction of anaemia with
erythropoietin normalises haemoglobin level and improves quality of life. Many aspects of the
impact of anaemia treatment with erythropoiesis-stimulating agents on the progression of CKD
remain unresolved and disputable. The present study is a retrospective chart review of 1654
outpatients with CKD. The data were collected from the Centre of Nephrology between 1 January
2002 and 31 December 2006. The aims of the study were to assess the causes of CKD; the
prevalence of anaemia based on the current guidelines for anaemia management in CKD (Kidney
Disease Dialysis Outcomes Quality Initiative; K/DOQI); to evaluate haemoglobin (Hb), systolic
and diastolic blood pressure (SBP and DBP), glomerular filtration rate (GFR) at the first referral to
a nephrologist and at the start of renal replacement therapy (RRT). The most common causes of
CKD were arterial hypertension (17.2%), chronic glomerulonephritis (17.2%), chronic intersticial
nephritis (13.3%), and diabetes (12.8%). Twenty-three percent of end-stage renal disease
(ESRD) patients had diabetes mellitus. At the first visit in the renal department, 16% of the pa-
tients had an advanced degree of CKD (GFR <30 ml/min). The proportion of patients under an
observation in the kidney centre for a period of six months and more was only 34% (554 of 1654).
Hypertension was recorded in 72% of study subjects. The blood pressure (BP) values in patients
at the first visit (n = 1633) vs. at the start of RRT (n = 154) were: mean SBP 147.4 ± 24.8 mm Hg
vs. 152.2 ± 23.0 mm Hg (P < 0.05); mean DBP 88.8 ± 13.6 mm Hg vs. 88.4 ± 12.0 mm Hg (P
0.05). Anaemia was recorded in 41% of study subjects, estimated using K/DOQI recommenda-
tions. The prevalence of anaemia was increased from 30.2% to 44.8% of study patients with a
rise of BP (from normal BP to hypertension; P < 0.05). The mean Hb level at the start of RRT was
9.8 ± 2.1 g/dl. Only 18% of patients with renal anaemia had used erythropoiesis-stimulating
agents before RRT (28 of 155). Anaemia is the prevalent condition at moderate degrees of CKD.
The severity of anaemia in the CKD population is determined by evidence of diabetes, cardiovas-
cular disease, and renal function. Anaemia may often be unrecognised or untreated.
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ease Dialysis Outcomes Quality Initiative; K/DOQI); to
evaluate haemoglobin (Hb), systolic and diastolic blood
pressure (SBP and DBP), glomerular filtration rate (GFR)
in patients at their first referral to a nephrologist and at the
start of renal replacement therapy (RRT).
PATIENTS AND METHODS
The study is a retrospective analysis involving one centre
and consists of data of 6520 consultations for CKD patients
during five years (2002–2006). The data was collected from
the archive of the Latvian Nephrology Centre. We studied
the prevalence of causes of underlying renal disease, distri-
bution of stages in CKD, clinical and laboratory findings on
the first visit in the kidney centre and at the start of RRT,
and the prevalence of anaemia and hypertension in patients
with CKD.
A total of 1654 patients were examined in the study. We se-
lected the following parameters: the data of patient visit,
gender, age, primary renal disease, outcome, systolic blood
pressure (SBP), diastolic blood pressure (DBP), weight,
presence of diabetes, use of erythropoiesis stimulating
agents (ESA), serum creatinine, haemoglobin (Hb) level,
and ferritin concentration. The outcomes of analysis were:
RRT, including hemodialysis (HD), peritoneal dialysis (PD)
and kidney transplantation (Tx); death; and continuation of
observation for each person on 31 December 2006. Ex-
cluded were patients who had pregnancy, acute infection,
systemic disease with active immunosuppressive therapy,
malignancy including haematological malignances, single
kidney, patients with previous or current RRT. The final
data set contained 4134 consultations of subjects with CKD.
For the purpose of this study, we use the definitions for
CKD, hypertension, anaemia as follows.
Classification and definition of chronic kidney disease.
According to the ERA-EDTA kidney disease coding sys-
tem, CKD was divided into eight groups (Fig. 1): I.
Glomerulonephritis; II. Pyelonephritis; III. Polycystic kid-
ney disease; IV. Hypertension; V. Renovascular disease;
VI. Diabetes mellitus; VII. Miscellaneous (chronic intersti-
tial nephritis, gout, lead nephropathy, occupational diseases,
systemic disorders etc.); VIII. Unknown diseases.
GFR and CKD classification according to stages. Glo-
merular filtration rate (GFR) was calculated using the
Cockcroft – Gault equation (Cockcroft and Gault, 1976):
GFR (ml/min) = [(140 – age, years) × (weight, kg)] / 72 ×
plasma creatinine, mg/dl. For women the result was multi-
plied by 0.85.
According to GFR, CKD was divided in five sequential
stages: stage I – GFR >90 ml/min; stage II – GFR 60–89
ml/min; stage III – GFR 30–59 ml/min; stage IV – GFR
15–29 ml/min; stage V – GFR <15 ml/min or dialysis
(Bolton et al., 2002).
Hypertension. The following definitions and classification
were suggested by the seventh report of the Joint National
Committee:
1. Normal blood pressure: systolic <120 mm Hg and dia-
stolic <80 mm Hg.
2. Pre-hypertension: systolic 120–139 mm Hg or diastolic
80–89 mm Hg.
3. Hypertension: Stage 1: systolic 140–159 mm Hg or dia-
stolic 90–99 mm Hg; Stage 2: systolic 160 mm Hg or dia-
stolic 100 mm Hg (Chobanian et al., 2003).
Anaemia. According to USA K/DOQI guidelines concern-
ing anaemia treatment in CKD patients, anaemia diagnosis
is credible when the Hb level is <13.5 g/dl in men and
<12.0 g/dl in women (Adamson et al., 2006).
Iron status also was calculated. Because our study had a ret-
rospective design and there was available only serum fer-
ritin concentration, we formulated the following criteria of
iron storage: adequate iron status was considered as serum
ferritin concentration of 100 ng/ml and iron deficiency was
considered as serum ferritin less then 100 ng/ml. The data
for transferrin saturation were not available and we did not
have the possibility to check functional iron deficiency.
All examined patients were selected by gender and by age
in following groups: 0–20; 21–44; 45–64; ≥65 years.
Statistical analysis. Statistical Package for the Social Sci-
ences (SPSS) version 15.0 software was used for all analy-
ses (SPSS Inc., Chicago, IL). Descriptive analyses are pre-
sented as mean with standard deviation or median with
range, depending on the underlying distribution. We used
t-tests, ANOVA for comparisons between parameters in in-
dependent groups. Pearson Chi-square or Mann-Whitney U
tests were used to compare qualitative variables. The crite-
rion for statistical significance was taken as a two-tailed P
value < 0.05.
RESULTS
Epidemiology. The causes of CKD in the enrolled popula-
tion were: hypertensive nephropathy (n = 284), chronic
glomerulonephritis (n = 284), intersticial nephritis (n =
220), diabetes mellitus (n = 211), pyelonephritis (n = 184),
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kidney disease of unknown origin (n = 127), polycystic kid-
ney disease (n = 82), systemic lupus erythematosus and
vasculites (n = 45), renal hypoplasia congenital — type un-
specified (n = 27), gout nephropathy (n = 27), renal vascu-
lar disease due to renal artery stenosis/occlusion (n = 25),
nephropathy due to analgesic drugs (n = 25), nephrocalci-
nosis (n = 23), hereditary nephropathy (n = 21), cystic kid-
ney disease — other specified type (n = 21), amyloid (n =
19), tubular necrosis (n = 8), tuberculosis (n = 6), other
identified renal disorders (n = 6), medullary cystic disease
(n = 4), lead induced nephropathy (n = 2), haemolytic ure-
mic syndrome (n = 1), sarcoidosis (n = 1), and trauma (n =
1). Diabetes was one of the most common causes for end-
stage renal disease (23%) followed by glomerulonephritis
(28%). Evidence of diabetes type 2 was observed in 44%
(16 of 36) of ESRD patients. The mean age of patients was
55.9 ± 17.1 years (n = 1654). The proportion of women in
the analysed population was significantly higher: 62.3%
(total n = 1654). In addition, female patients were older
than male: 57.5 ± 16.1 years in female and 54.1 ± 18.3
years in male (P < 0.001).
At the start of dialysis therapy mean age was 54.2 ± 16.0 (n
= 155). Furthermore, 73.5% of them were part of the able-
bodied population and 26.5% were above 65 years old.
Forty-eight percent of patients were female (75 of 155).
There was no significant difference in mean age between
female and male patients with ESRD: 53.6 years versus
54.8 years (P > 0.05).
The majority of patients with different stages of CKD (840
of 1654) visited the Centre of Nephrology only once. The
patients with repeated visits to a nephrologists had the fol-
lowing distributions of time under the observation: 8.1% (n
= 67) for <1 month; 23.7% (n = 193) for 1 to 6 months;
17.2% (n = 140) for 6 to 12 months; 21.9% (n = 178) for 12
to 24 months; and 29% (n = 236) patients were under care
of a nephrologist for over two years. The mean duration of
the time under care of a nephrologist for patients who were
observed repeatedly was 17.6 months, range from 1 to 59
months. Median period of time under care of a nephrologist
for these patients was 13 months. At the visit to dialysis de-
partment, 14% (21 of 155) of the ESRD patients had visits
for the first time. Thirteen patients were observed for one
month; 22 patients for 1 to 6 months; 24 patients for 6 to 12
months; 38 patients for 12 to 24 months; 20 patients for 2–3
years; and 17 patients over three years. The mean observa-
tion period before start of dialysis therapy for patients with
repeated consultation was 17.4 months, ranged from 1 to 53
months. Median length of the time under care of a neph-
rologist for patients who were observed repeatedly before
initiation of RRT was 15 months. Peritoneal dialysis was
started for 50 (32%) patients, haemodialysis for 103 (67%)
patients, and 2 (1%) patients had preemptive kidney trans-
plantations.
At the time of first referral, 54% (893 of 1653) of patients
presented clinically impaired renal function (GFR <60
ml/min). The distribution of CKD for all patients at the first
visit to a nephrologist was as follows (Table 1). By stage,
an estimated 311 subjects (18.8%) had stage I; 441 (27.2%)
stage II; 622 (37.6%) stage III; 227 (13.7%) stage IV; and
44 (2.7%) had end-stage renal disease. At the start of RRT
(haemodialysis or peritoneal dialysis) GFR ranged from 3.5
ml/min to 29.8 ml/min. Mean GFR and standard deviation
was 12.9 ± 5.1 ml/min. In addition, 33% (47 of 144) of
these patients had glomerular filtration rate above 15
ml/min. Unfortunately, we lacked information on some clin-
ical details for starting dialysis therapy because the study
had a retrospective design.
Hypertension. Hypertension was the prevalent condition in
patients with CKD (Fig. 2). At a patient first visit to a
nephrologist normal blood pressure was estimated only in
5.8% (96 of 1654). Pre-hypertension and hypertension were
recorded in 22.1% (365 of 1654) and 72.1% (1192 of 1654)
of patients, respectively. In addition, subjects with hyper-
tension stage 1 and stage 2 were recorded in 29.1% and
43.0%, of cases, respectively. At the start of dialysis ther-
apy systolic blood pressure was significantly higher com-
pared with patients without RRT: 152.2 ± 23.0 mm Hg vs.
147.4 ± 24.8 mm Hg (P < 0.05). No difference in the dia-
stolic blood pressure record was found across CKD patients
(with or without RRT) (P > 0.05).
Anaemia. At the first visit to Centre of Nephrology, hae-
moglobin level was determined in 72% of patients with
CKD (1179 of 1633 patients). Haemoglobin level ranged
from 6.3 g/dl to 18.1 g/dl, with a mean and standard devia-
tion of 12.7 ± 2.0 g/dl (Fig. 3). Median haemoglobin level
for these study patients was 13 g/dl. Baseline haemoglobin
levels for 143 patients with RRT (92%; total n = 155 pa-
tients) are illustrated in Figure 4. There was missing data
T a b l e 1
DISTRIBUTION OF CHRONIC KIDNEY DISEASE (CKD) FOR ALL
EXAMINED PATIENTS AT THE FIRST VISIT
Stage GFR (ml/min) Patients, n (%)
I 90 311 (18.8)
II 60–89 441 (27.2)
III 30–59 622 (37.6)
IV 15–29 227 (13.7)
V <15 or dialysis 44 (2.7)
GFR, glomerular filtration rate.
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Fig. 2. Prevalence of hypertension in patients with chronic kidney disease
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for haemoglobin level in 12 patients with RRT. Haemoglo-
bin level ranged from 5.1 g/dl to 14.6 g/dl, with a mean and
standard deviation of 9.8 ± 2.1 g/dl. Median haemoglobin
level for ESRD patients was 9.6 g/dl.
Evidence of anaemia was estimated at the first visit in kid-
ney centre for all patients, including patients with RRT (to-
tal n = 1644). Patients with erythropoietin therapy were ex-
cluded. At the first visit to a nephrologist there was missing
data for serum haemoglobin level in 455 patients (28%, to-
tal number = 1644). Forty one percent of patients (n = 487)
had been diagnosed as anaemic using K/DOQI recommen-
dations.
The study results demonstrated that with progression of
CKD haemoglobin concentration considerably decreased.
Figure 5 shows decrease of haemoglobin level in diabetic
and non-diabetic kidney diseases (P < 0.001). Mean hae-
moglobin levels for diabetic versus non-diabetic patients
were 13.5 ± 1.6 g/dl vs. 14.1 ± 1.6 g/dl; 13.2 ± 1.5 g/dl vs.
13.5 ± 1.5 g/dl; 12.4 ± 1.8 g/dl vs. 13.0 ± 1.7 g/dl; 10.3 ±
1.5 g/dl vs. 11.2 ± 1.9 g/dl; 9.4 ± 1.5 g/dl vs. 9.4 ± 1.9 g/dl
in stage I, II, III, IV, V CKD, respectively (Fig. 5).
The association between blood pressure and the prevalence
of anaemia estimated by K/DOQI are presented on Figure 6.
Haemoglobin concentration data was missing in 485 pa-
tients. The percentage anaemic patients with CKD was pro-
gressively higher with increased arterial blood pressure
(Pearson Chi-square test; P < 0.05).
Serum ferritin level in subjects with GFR < ml/min was
checked in only 13% of cases. Serum ferritin ranged from
1.1 ng/ml to 1196 ng/ml. Median serum ferritin level for
these study patients was 121 ng/ml.
Only 18% of patients with renal anaemia had used erythro-
poiesis-stimulating agents before RRT (28 of 155).
DISCUSSION
This is the first study in Latvia on CKD patients observed
during a five-year period. We found that the most common
causes of chronic kidney disease were arterial hypertension
(17.2%), chronic glomerulonephritis (17.2%), chronic
intersticial nephritis (13.3%), and diabetes (12.8%). More-
over, the proportion of patients with diabetes as the primary
cause of ESRD in Latvia was 23%. Diabetes is the leading
cause of CKD developing countries. High prevalence and
incidence of diabetic kidney disease in the CKD population
has been reported in previous publications (Zimmet et al.,
























Fig. 3. Distribution of haemoglobin level in pa-
tients with chronic kidney disease (CKD) before
renal replacement therapy (RRT) (n =1179).
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Fig. 4. Distribution of haemoglobin level in patients with renal replace-
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United States has recently stabilised, however, it had grown
by nearly 60% and the rate per million population in 2005
remained at 152 (Collins et al., 2007).
The mean age of patients at the start of RRT in our study
was 54.2 years. PRESAM results showed that the mean age
of incident dialysis patients was 59.1 years (Valderrábano et
al., 2003). The USRDS data demonstrated an estimated
mean age of 62.7 years in incident ESRD patients (Collins
et al., 2007). The possible factors for this difference may be
insufficient control and diagnostics of chronic kidney dis-
ease before dialysis treatment in Latvia. Secondly, the mean
age of incident ESRD patients performed by USRDS was
based on the general population, while our results reflect
data from a single centre.
Most of the patients (16%) presented as a late referral to a
renal centre (GFR <30 ml/min). Fifty four percent of all
analysed patients at first visit to a nephrologist had GFR be-
low 60 ml/min. About a half of all patients (50.8%) were in
a kidney centre only once. The patients with duration of the
time under care of a nephrologist at least six months and
over were 33.5%: 8.5% for 6 to 12 months; 10.8% for 12 to
24 months; 6.8% for two to three years; and 7.4% for three
and over years. In addition, at the first visit to dialysis de-
partment, 14% (21 of 155) of patients started RRT
immediately. This finding shows that, at first, most of the
patients present to the renal department with advanced de-
grees of CKD. Secondly, only one-third of the patients were
under care of nephrologists for over six months. Similar
data have been published elsewhere. Hörl et al. summarised
data of a major retrospective study PRESAM (PREdialysis
Survey on Anaemia Management) covering information on
4333 CKD patients from 23 countries, published in 2003,
and made several practical conclusions. One of the most
common problems was late nephrologist referral for pa-
tients with progressing renal failure, which once again made
poor condition of renoprotective and cardioprotective treat-
ment strategies an issue as patients enter nephrology centre
late: average GFR at first visit was 18.2 ml/min (Hörl et al.,
2003).
Hypertension was a prevalent condition in patients with
CKD in our study patients. Hypertension was recorded in
72% of the patients. Hörl et al. (2003) presented 78% pa-
tients with CKD and hypertension. This report is distinctive
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Fig. 5. Haemoglobin level in diabetic versus
non-diabetic patients by chronic kidney disease
(CKD) stage; pts, patients; D, diabetics; non-D,
non-diabetics; **P < 0.05.
Fig. 6. Prevalence of anaemia depending on
blood pressure (BP).
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We used the classification of blood pressure suggested by
the 7th report of the JNC and hypertension was defined as
systolic blood pressure above 140 mm Hg or diastolic
above 90 mm Hg, while PRESAM study researchers de-
fined hypertension as the blood pressure above 145/95 mm
Hg (Hörl et al., 2003). In our study, the prevalence of anae-
mia was significantly associated with a rise of arterial blood
pressure. In a retrospective study by Phillipp et al. (2005),
logistic regression was performed to evaluate the relative
risk for several variables, including hypertension, on anae-
mia in 2941 patients with CKD. They found that arterial hy-
pertension itself had no influence on anaemia, since diabe-
tes was an independent risk factor on haemoglobin level and
had an relative risk of 1.8 (95%CI; 1.28 – 2.54; P < 0.05)
(Phillipp et al., 2005). However, the left ventricular hyper-
trophy and heart failure as the consequences of chronic arte-
rial hypertension and its relationship with the anaemia in
predialysis patients is clearly considered in numerous stud-
ies (Foley et al., 1998; Levin et al., 1999; Jurkovitz et al.,
2003; Phillipp et al., 2005; Vlagopoulos et al., 2005;
Drüeke et al., 2006).
Anaemia is one of the most common manifestations in
CKD patients. The results of the retrospective analysis of
this study suggest that anaemia among patients with stages
I – V CKD is very common. According to USA guidelines
on anaemia diagnostics, anaemia in CKD patients (Hb
<13.5 g/dl in men and <12.0 g/dl in women) was diagnosed
41% of patients (n = 487). The mean haemoglobin level of
patients at the start of RRT in our study was 9.8 g/dl, which
is similar with that in the PRESAM report, estimated as be-
low 10 g/dl (Hörl, 2003). The Levin et al. study results
show than mean haemoglobin in patients with GFR <15
ml/min was 9.9 g/dl (Levin et al., 2006). Only 18% of pa-
tients with renal anaemia had used erythropoietin prior to
RRT. However, despite the high prevalence of anaemia in
CKD patients, haemoglobin level was not determined in
28% of subjects. This obviously reveals indicates lack of in-
formation concerning CKD in the context of primary medi-
cal care. Clinical manifestations of anaemia emerge if the
haemoglobin level falls to <11 g/dl, which is the reason
why erythropoietin therapy and iron supplementation is rec-
ommended during this period according to main guidelines.
However, as demonstrated in our study by a low proportion
of patients undergoing anaemia treatment with erythropoie-
tin, primary care physicians may not be aware of the critical
importance of screening for anaemia in the CKD population
and anaemia may often be unrecognised or untreated.
The association between impaired renal function, anaemia
and diabetes is well recognised in several studies (Bosman
et al., 2001; El-Achkar et al., 2005; Ravanan et al., 2007).
Anaemia in diabetic nephropathy is more severe than seen
in patients with non-diabetic kidney disease. Several studies
have suggested that anaemia occurs at an earlier stage of the
disease and is more severe in patients with diabetic
nephropathy than in non-diabetic kidney disease patients.
Ravanan et al. (2007) reported that mean haemoglobin lev-
els in diabetic patients compared with those in non-diabetics
were 129.5 vs. 136.9 g/l (P < 0.01), 120.5 vs. 126.9 g/l (P <
0.01) and 107.1 vs. 115.9 g/l (P < 0.01) at stages III, IV and
V CKD, respectively (Ravanan et al., 2007). Bosman et al.
(2001) compared 27 patients with diabetic nephropathy with
26 non-diabetic patients with glomerulonephritis and dem-
onstrated that anaemia was presented in 13 of the 27 diabet-
ics (mean Hb 10.6 ± 0.9 g/dl), in marked contrast to
non-diabetics (mean Hb 13.7 ± 0.9 g/dl; P < 0.05) (Bosman
et al., 2001). The result of our study is similar. We show
that the diabetic nephropathy in patients with stage III – V
CKD is associated with more severe anaemia than non-dia-
betic patients (P < 0.001).
The main limitations of our study are the retrospective anal-
ysis design and missed factors to control. Therefore, the
completed data for several variables, including erythropoie-
tin therapy regimen, usage of iron, comorbidities (cardio-
vascular diseases, excluding hypertension) with its treatment
possibilities, and other clinical significant manifestations in
patients with CKD (secondary hyperparathyreoidism, mal-
nutrition, dislipidemia) were not available, and maybe, can
impact on our study derived results. However, despite this
study weakness, we can conclude that anaemia is commonly
observed among subjects with stage III –V CKD and more
often in diabetics. Diabetic kidney disease is associated with
lower haemoglobin levels in comparison with non-diabetic
kidney disease. Despite the high prevalence of anaemia in
the examined patients, erythropoietin therapy is underused.
We hope that this finding may result in multidisciplinary
healthcare team doctors to regularly monitor haemoglobin
level and provide timely treatment with erythropoietin and
iron supplementations.
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RENÂLÂ ANÇMIJA: HEMOGLOBÎNA LÎMEÒA NOTEIKÐANAS NOZÎME SLIMNIEKIEM AR HRONISKU NIERU SLIMÎBU
Hroniska nieru slimîba (HNS) ir nozîmîga sabiedrîbas veselîbas problçma pasaules mçrogâ. Ançmija ir viena no bieþâkâm HNS
izpausmçm. Ançmijas ârstçðana ar eritropoçzi veicinoðiem medikamentiem labvçlîgi ietekmç HNS attîstîbu, slimnieka dzîves kvalitâti un
sirds un asinsvadu sistçmu. Darbâ ir retrospektîvi analizçti 1654 slimnieki ar HNS (P. Stradiòa Klîniskâs universitâtes slimnîcas
Nefroloìijas centra arhîva materiâli no 2002. lîdz 2006. gadam). Pçtîjuma mçríis bija izpçtît HNS pamatcçloòus, HNS slimnieku
novçroðanas ilgumu, arteriâlâs hipertensijas bieþumu, ançmijas bieþumu, smagumu un ârstçðanas iespçjas slimniekiem ar HNS. Saskaòâ ar
ASV vadlînijâm par ançmijas ârstçðanu HNS slimniekiem (KDOQI 2006) ançmijas diagnoze bija ticama, ja hemoglobîna (Hb) lîmenis bija
<13,5 g/dl vîrieðiem un <12,0 g/dl sievietçm. Pçtîjuma rezultâti liecina, ka visbieþâkie HNS cçloòi bija hipertensîvâ nefropâtija (17,2%),
hronisks glomerulonefrîts (17,2%), hronisks intersticiâls nefrîts (13,3%), cukura diabçts (12,8%). Bez tam cukura diabçts kâ terminâlas
nieru mazspçjas cçlonis bija 23% slimnieku ar nieru aizstâjterapiju (NAT). Pirmâ vizîtç 16% slimniekiem tika konstatçta progresçjoða nieru
slimîba (glomerulu filtrâcijas âtrums <30 ml/min). Pçtîjuma rezultâti liecina, ka tikai 34% (554 no 1654) analizçto slimnieku bija regulâra
ilglaika (>6 mçneði) ambulatoriskâ novçroðana pie nefrologa. Arteriâlâ hipertensija tika konstatçta 72% dalîbnieku. Vidçjais asinsspiediens
pçtîjuma slimniekiem pirmajâ vizîtç (n = 1633) vs. NAT sâkðanas brîdî (n = 154) bija ðâds: vidçjais sistoliskais asinsspiediens (SAS) –
147,4 ± 24,8 mm Hg vs. 152,2 ± 23,0 mm Hg (p <0,05); vidçjais diastoliskais asinsspiediens (DAS) – 88,8 ± 13,6 mm Hg vs. 88,4 ± 12,0
mm Hg (p >0.05). Saskaòâ ar ASV rekomendâcijâm par ançmijas diagnostiku un ârstçðanu, ançmija tika konstatçta 41% analizçto
slimnieku. Ançmijas bieþums korelç ar arteriâlo hipertensiju: no 30,2% slimniekiem ar normâlu arteriâlo asinsspiedienu lîdz 44,8%
dalîbniekiem ar hipertensijas 2. pakâpi (P < 0,05). Vidçjais Hb lîmenis, sâkot NAT, bija 9,8 ± 2,1 g/dl. Vidçjais Hb lîmenis slimniekiem ar
cukura diabçtu bija ticami zemâks nekâ slimniekiem ar citu HNS pamatpatoloìiju. Eritropoetînterapijas lietoðana pirmsdialîzes periodâ tika
konstatçta tikai 18% HNS slimnieku ar ançmiju. Ançmija ir viena no bieþâkâm HNS klîniskâm izpausmçm HNS slimniekiem. Ançmijas
bieþumu un smagumu nosaka blakus slimîbas (piem., cukura diabçts, sirds asinsvadu sistçmas slimîbas) un nieru funkcija (HNS stadija).
Ançmija bieþi vien netiek diagnosticçta un ârstçta.
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